查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026809

透納氏症市場預測至2034年—按類型、藥物類型、治療方法、診斷方法、給藥途徑、最終用戶和地區分類的全球分析

Turner Syndrome Market Forecasts to 2034 - Global Analysis By Type, Drug Type, Therapy Type, Diagnosis, Route Of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球透納氏症市場規模將達到 53 億美元，並在預測期內以 8.1% 的複合年成長率成長，到 2034 年將達到 98 億美元。

透納氏症是一種影響女性的染色體異常疾病，由X染色體缺失或不完整所引起。正常情況下，女性擁有兩條X染色體（XX），但透納氏症患者要麼缺少一條X染色體（X0），要麼其中一條X染色體存在異常。患有透納氏症的女孩通常有一些特定的體徵，例如身材矮小、頸部皮膚褶皺（額外的皮膚褶皺）、胸部寬闊、耳位低以及腭弓高聳。

根據美國國家醫學圖書館 2017 年的報告，全世界大約每 2500 名新生女嬰中就有 1 名被診斷出患有透納氏症。

加強病患支持活動和提高公眾意識

病患權益倡導在爭取改善醫療服務和治療的可及性方面發揮著至關重要的作用。這種計劃通常延伸至旨在改善透納氏症罕見疾病患者整體環境的政策建議。提高公眾意識往往有助於更早發現透納氏症，並在宣傳活動、研究支持和倡導更有效的治療方法方面發揮著至關重要的作用。這些組織促進了研究人員、臨床醫生和製藥公司之間的合作。

患者數量有限

透納氏症是一種罕見疾病，發生率約兩千分之一。因此，取得必要的自然病程資料十分有限。患者群體較小，難以收集足夠的真實世界證據，這可能會阻礙對治療方法長期效果的理解。此外，確定治療方法價值和獲得保險覆蓋也更為複雜。這些因素進一步加劇了問題的複雜性，並阻礙了市場成長。

未滿足的醫療需求

透納氏症是一種罕見疾病，存在許多未被滿足的醫療需求，亟需有效且有針對性的治療方法。解決這些需求需要醫療專業人員、研究人員和製藥公司之間的合作。標靶治療的開發有望顯著改善透納氏症的治療，並帶來更有效、更個人化的治療方案。對於製藥公司而言，這為開發創新治療方法並加速市場擴張提供了機會。

高昂的開發成本

開發針對透納氏症罕見疾病的治療方法往往面臨獨特的挑戰，導致研發成本飆升。潛在患者數量有限，使得製藥公司投資透納氏症藥物和治療方法成為一項財務上的巨大挑戰。此外，闡明潛在的遺傳機制、進行臨床前試驗以及應對罕見疾病的監管流程都需要專門的專業知識和資源。這些因素綜合起來可能會阻礙市場成長。

新冠疫情的感染疾病

全球醫療服務受到新冠肺炎疫情的嚴重衝擊。疫情導致資源轉移，使得透納氏症非緊急疾病的治療延誤。患者在獲取常規檢查、治療和支持服務方面面臨許多挑戰。此外，醫藥供應鏈中斷也影響了透納氏症相關藥物和其他醫療產品的供應。目前，市場已恢復至疫情前水準。

在預測期內，Genotropin產業預計將是規模最大的產業。

Genotropin片段展現出良好的生長潛力。Genotropin通常作為綜合治療方案的一部分，該方案包括荷爾蒙補充療法和其他干預措施，旨在改善透納氏症的各個方面。這有助於提高透納氏症患者的生活品質。其益處眾多，包括改善身體組成、骨骼健康和心血管健康、減輕矮小身材以及促進整體生長發育。

在預測期內，產前檢測領域預計將呈現最高的複合年成長率。

預計在預測期內，產前檢測領域將呈現最高的複合年成長率。產前檢測在透納氏症的早期診斷中發揮著至關重要的作用。早期診斷有助於及時介入和採取適當的治療策略，從而可能改善患者的預後。在懷孕期間了解這種疾病可以讓父母做好心理準備，並應對與疾病相關的挑戰。隨著技術和基因檢測技術的不斷發展，透納氏症產前檢測的準確性和可及性有望提高，從而進一步增強其在患者照護和家庭計劃中的作用。

市佔率最大的地區：

預計在預測期內，亞太地區將佔據最大的市場佔有率，這主要得益於女性健康意識的提高、醫療保健支出的成長以及醫療保健行業的蓬勃發展。印度的醫療保健產業一直是成長最快的產業之一。印度和中國等開發中國家正大力投資醫療基礎設施、醫療專家以及研發活動。因此，醫療保健支出的成長，加上女性遺傳疾病發生率的上升，正在推動該地區透納氏症市場的成長。

複合年成長率最高的地區：

預計在預測期內，歐洲將呈現最高的複合年成長率。歐洲擁有眾多領先企業，包括諾華、益普生和賽諾菲健贊。這些公司在罕見遺傳疾病相關研究領域投入巨資，並經常發布前沿創新成果和解決方案。此外，罕見疾病技術創新的進步、龐大的患者群體、唐氏症認知度的提高以及生物技術產業的蓬勃發展，都在推動該地區市場成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章：全球透納氏症市場：按類型分類

  • 嵌合型透納氏症
  • 經典透納氏症

第6章：全球透納氏症市場：依藥物類型分類

  • Oxandrolone
  • Oxandrin
  • 諾德特羅平
  • Somatropin
  • Genotropin
  • Humatrope
  • Zomacton
  • Nutropin

第7章：全球透納氏症市場：依治療方法

  • 黃體素替代療法
  • 雌激素替代療法
  • 生長激素荷爾蒙療法
  • 心理治療
  • 其他治療方法

第8章：全球透納氏症市場：依診斷分類

  • 身體檢查
  • 核型分析
  • 產前檢查
    • 羊膜穿刺術
    • 超音波檢查
    • 絨毛膜絨毛取樣
  • 其他診斷

第9章：全球透納氏症市場：依給藥途徑分類

  • 口服
  • 皮下
  • 靜脈
  • 肌肉內部
  • 其他給藥途徑

第10章：全球透納氏症市場：以最終用戶分類

  • 研究機構
  • 醫院和診所
  • 學術機構
  • 其他最終用戶

第11章：全球透納氏症市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第12章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章：公司簡介

  • Smiths Group
  • Pfizer Inc.
  • Rocket Medical PLC
  • Medtronic
  • Novo Nordisk
  • Sanofi
  • Cooper Pharma
  • Eli Lilly and Company
  • Genentech
  • Lupin Pharmaceuticals Inc
  • Sandoz International GmbH
  • AbbVie Inc.
  • Codexis
  • Merck & Co.
  • American Gene Technologies
  • Johnson & Johnson Services Inc
  • F. Hoffmann-La Roche Limited
  • Ultragenyx Pharmaceutical
  • Abbott Laboratories
  • BioMarin
Product Code: SMRC24620

According to Stratistics MRC, the Global Turner Syndrome Market is accounted for $5.3 billion in 2026 and is expected to reach $9.8 billion by 2034 growing at a CAGR of 8.1% during the forecast period. Turner syndrome is a chromosomal condition that affects females and results from a missing or incomplete X chromosome. Typically, females have two X chromosomes (XX), but individuals with Turner syndrome have either a missing X chromosome (X0) or abnormalities in one of the X chromosomes. Girls with turner syndrome often have specific physical characteristics including short stature, a webbed neck (extra folds of skin), a broad chest, low-set ears, and a high-arched palate.

According to the National Library of Medicine in 2017, about 1 in 2,500 new-born girls, worldwide, were affected with the Turner Syndrome.

Market Dynamics:

Driver:

Rising patient advocacy and awareness

Patient advocacy plays a crucial role in advocating for improved access to healthcare services and treatments. It often extends to policy initiatives aimed at improving the overall landscape for individuals with rare diseases like turner syndrome. Increased awareness often leads to early detection of Turner syndrome. It plays a crucial role in raising awareness, supporting research, and advocating for better treatment options. These groups facilitates collaboration between researchers, clinicians, and pharmaceutical companies.

Restraint:

Limited patient population

Turner Syndrome is a rare disorder which occurs in mostly one out of 2000 girls. So, there is less availability of natural history data, which is crucial for understanding the progression of the disease. Limited patient numbers makes it challenging to gather sufficient real-world evidence, potentially hindering the understanding of the long-term impact of therapies. Also, establishing the value of a therapy and securing reimbursement can be more complex. This aspect raises the complexities and hampers the market growth.

Opportunity:

Unmet medical needs

Turner Syndrome is a rare disorder and it presents several unmet medical needs that need effective and targeted therapies. Addressing these unmet medical needs requires collaboration between healthcare professionals, researchers, and pharmaceutical companies. The development of targeted therapies could significantly improve the management of Turner Syndrome, potentially leading to more effective and personalized treatment options. Pharmaceutical companies may see this as an opportunity to develop innovative treatments which in turn accelerates the market expansion.

Threat:

High development costs

The development of therapies for rare conditions such as turner syndrome often faces unique challenges, leading to high development costs. The limited number of potential patients makes it economically challenging for pharmaceutical companies to invest in the development of drugs or therapies for turner syndrome. Also, understanding the underlying genetic mechanisms, conducting preclinical studies, and navigating the regulatory processes for rare diseases require specialized expertise and resources. The combination of these factors can hamper the growth of the market.

Covid-19 Impact

Global healthcare services have been severely impacted by the COVID-19 epidemic. Due to the pandemic, resources were redirected, which caused delays in the treatment of non-urgent medical disorders, such as Turner syndrome. Patients have faced challenges in accessing regular check-ups, treatments, and support services. Additionally, the supply chain for the pharmaceutical sector experienced interruptions that impacted the availability of drugs and other healthcare supplies related to Turner syndrome. The market has further recovered to its pre-pandemic level.

The genotropin segment is expected to be the largest during the forecast period

The genotropin segment is estimated to have a lucrative growth. Genotropin is often used as part of a comprehensive treatment approach that includes hormone replacement therapy and other interventions to address various aspects of turner syndrome. It contributes to an improved quality of life for individuals with turner syndrome. It exhibits numerous benefits such as improved body composition, bone health, cardiovascular health, improvement of short stature and overall body growth.

The prenatal testing segment is expected to have the highest CAGR during the forecast period

The prenatal testing segment is anticipated to witness the highest CAGR growth during the forecast period. Prenatal testing plays a crucial role in the early diagnosis of turner syndrome. This early diagnosis can lead to timely interventions and appropriate management strategies, potentially improving outcomes for the affected individual. Knowing about the disorder during pregnancy allows parents to emotionally prepare for the challenges associated with the condition. As technology and genetic testing methods continue to advance, the accuracy and accessibility of prenatal testing for turner syndrome are likely to improve, further enhancing its role in patient care and family planning.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increasing awareness for women health, rising healthcare expenditures and growing healthcare sector. The Indian healthcare sector was one of the fastest growing industries. The developing countries like the India and China are investing heavily on healthcare infrastructure, professional doctors and R&D activities. Therefore, the increasing expenditure coupled with rising regularity of genetic disorders in females leads to the growth of the turner syndrome market in this region.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. Europe is home to several key players such as Novartis, Ipsen and Sanofi Genzym. These companies invest hugely on research activities related to rare genetic diseases. They often bring out latest innovations and solutions. Further, rise in technological innovations for rare disorders, huge patient population, increasing awareness regarding down syndromes and growing biotechnology sector are boosting the region's market growth.

Key players in the market

Some of the key players profiled in the Turner Syndrome Market include Smiths Group, Pfizer Inc., Rocket Medical PLC, Medtronic, Novo Nordisk, Sanofi, Cooper Pharma, Eli Lilly and Company, Genentech, Lupin Pharmaceuticals Inc, Sandoz International GmbH, AbbVie Inc., Codexis, Merck & Co., American Gene Technologies, Johnson & Johnson Services Inc, F. Hoffmann-La Roche Limited, Ultragenyx Pharmaceutical, Abbott Laboratories and BioMarin.

Key Developments:

In October 2023, Novo Nordisk, a subsidiary of Novo Holdings AS, unveils Somapacitan (Sogroya) is a human growth hormone analog. It is formulated as solution for subcutaneous route of administration. Sogroya is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (GHD).

In March 2023, Sanofi and Provention Bio Inc, have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc. The acquisition is a strategic fit for Sanofi at the intersection of the company's growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet need, and its expertise in diabetes.

Types Covered:

  • Mosaic Turner Syndrome
  • Classical Turner Syndrome

Drug Types Covered:

  • Oxandrolone
  • Oxandrin
  • Norditropin
  • Somatropin
  • Genotropin
  • Humatrope
  • Zomacton
  • Nutropin

Therapy Types Covered:

  • Progesterone Replacement Therapy
  • Oestrogen Replacement Therapy
  • Growth Hormone Therapy
  • Psychological Therapy
  • Other Therapy Types

Diagnosis Covered:

  • Physical Examination
  • Karyotyping
  • Prenatal Testing
  • Other Diagnosis

Route Of Administrations Covered:

  • Oral
  • Sub-cutaneous
  • Intravenous
  • Intramuscular
  • Other Route Of Administrations

End Users Covered:

  • Research Organizations
  • Hospitals & Clinics
  • Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Turner Syndrome Market, By Type

  • 5.1 Introduction
  • 5.2 Mosaic Turner Syndrome
  • 5.3 Classical Turner Syndrome

6 Global Turner Syndrome Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Oxandrolone
  • 6.3 Oxandrin
  • 6.4 Norditropin
  • 6.5 Somatropin
  • 6.6 Genotropin
  • 6.7 Humatrope
  • 6.8 Zomacton
  • 6.9 Nutropin

7 Global Turner Syndrome Market, By Therapy Type

  • 7.1 Introduction
  • 7.2 Progesterone Replacement Therapy
  • 7.3 Oestrogen Replacement Therapy
  • 7.4 Growth Hormone Therapy
  • 7.5 Psychological Therapy
  • 7.6 Other Therapy Types

8 Global Turner Syndrome Market, By Diagnosis

  • 8.1 Introduction
  • 8.2 Physical Examination
  • 8.3 Karyotyping
  • 8.4 Prenatal Testing
    • 8.4.1 Amniocentesis
    • 8.4.2 Ultrasound Test
    • 8.4.3 Chorionic Villus Sampling
  • 8.5 Other Diagnosis

9 Global Turner Syndrome Market, By Route Of Administration

  • 9.1 Introduction
  • 9.2 Oral
  • 9.3 Sub-cutaneous
  • 9.4 Intravenous
  • 9.5 Intramuscular
  • 9.6 Other Route Of Administrations

10 Global Turner Syndrome Market, By End User

  • 10.1 Introduction
  • 10.2 Research Organizations
  • 10.3 Hospitals & Clinics
  • 10.4 Academic Institutes
  • 10.5 Other End Users

11 Global Turner Syndrome Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Smiths Group
  • 13.2 Pfizer Inc.
  • 13.3 Rocket Medical PLC
  • 13.4 Medtronic
  • 13.5 Novo Nordisk
  • 13.6 Sanofi
  • 13.7 Cooper Pharma
  • 13.8 Eli Lilly and Company
  • 13.9 Genentech
  • 13.10 Lupin Pharmaceuticals Inc
  • 13.11 Sandoz International GmbH
  • 13.12 AbbVie Inc.
  • 13.13 Codexis
  • 13.14 Merck & Co.
  • 13.15 American Gene Technologies
  • 13.16 Johnson & Johnson Services Inc
  • 13.17 F. Hoffmann-La Roche Limited
  • 13.18 Ultragenyx Pharmaceutical
  • 13.19 Abbott Laboratories
  • 13.20 BioMarin

List of Tables

  • Table 1 Global Turner Syndrome Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Turner Syndrome Market Outlook, By Type (2023-2034) ($MN)
  • Table 3 Global Turner Syndrome Market Outlook, By Mosaic Turner Syndrome (2023-2034) ($MN)
  • Table 4 Global Turner Syndrome Market Outlook, By Classical Turner Syndrome (2023-2034) ($MN)
  • Table 5 Global Turner Syndrome Market Outlook, By Drug Type (2023-2034) ($MN)
  • Table 6 Global Turner Syndrome Market Outlook, By Oxandrolone (2023-2034) ($MN)
  • Table 7 Global Turner Syndrome Market Outlook, By Oxandrin (2023-2034) ($MN)
  • Table 8 Global Turner Syndrome Market Outlook, By Norditropin (2023-2034) ($MN)
  • Table 9 Global Turner Syndrome Market Outlook, By Somatropin (2023-2034) ($MN)
  • Table 10 Global Turner Syndrome Market Outlook, By Genotropin (2023-2034) ($MN)
  • Table 11 Global Turner Syndrome Market Outlook, By Humatrope (2023-2034) ($MN)
  • Table 12 Global Turner Syndrome Market Outlook, By Zomacton (2023-2034) ($MN)
  • Table 13 Global Turner Syndrome Market Outlook, By Nutropin (2023-2034) ($MN)
  • Table 14 Global Turner Syndrome Market Outlook, By Therapy Type (2023-2034) ($MN)
  • Table 15 Global Turner Syndrome Market Outlook, By Progesterone Replacement Therapy (2023-2034) ($MN)
  • Table 16 Global Turner Syndrome Market Outlook, By Oestrogen Replacement Therapy (2023-2034) ($MN)
  • Table 17 Global Turner Syndrome Market Outlook, By Growth Hormone Therapy (2023-2034) ($MN)
  • Table 18 Global Turner Syndrome Market Outlook, By Psychological Therapy (2023-2034) ($MN)
  • Table 19 Global Turner Syndrome Market Outlook, By Other Therapy Types (2023-2034) ($MN)
  • Table 20 Global Turner Syndrome Market Outlook, By Diagnosis (2023-2034) ($MN)
  • Table 21 Global Turner Syndrome Market Outlook, By Physical Examination (2023-2034) ($MN)
  • Table 22 Global Turner Syndrome Market Outlook, By Karyotyping (2023-2034) ($MN)
  • Table 23 Global Turner Syndrome Market Outlook, By Prenatal Testing (2023-2034) ($MN)
  • Table 24 Global Turner Syndrome Market Outlook, By Amniocentesis (2023-2034) ($MN)
  • Table 25 Global Turner Syndrome Market Outlook, By Ultrasound Test (2023-2034) ($MN)
  • Table 26 Global Turner Syndrome Market Outlook, By Chorionic Villus Sampling (2023-2034) ($MN)
  • Table 27 Global Turner Syndrome Market Outlook, By Other Diagnosis (2023-2034) ($MN)
  • Table 28 Global Turner Syndrome Market Outlook, By Route Of Administration (2023-2034) ($MN)
  • Table 29 Global Turner Syndrome Market Outlook, By Oral (2023-2034) ($MN)
  • Table 30 Global Turner Syndrome Market Outlook, By Sub-cutaneous (2023-2034) ($MN)
  • Table 31 Global Turner Syndrome Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 32 Global Turner Syndrome Market Outlook, By Intramuscular (2023-2034) ($MN)
  • Table 33 Global Turner Syndrome Market Outlook, By Other Route Of Administrations (2023-2034) ($MN)
  • Table 34 Global Turner Syndrome Market Outlook, By End User (2023-2034) ($MN)
  • Table 35 Global Turner Syndrome Market Outlook, By Research Organizations (2023-2034) ($MN)
  • Table 36 Global Turner Syndrome Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 37 Global Turner Syndrome Market Outlook, By Academic Institutes (2023-2034) ($MN)
  • Table 38 Global Turner Syndrome Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.